HIGHLIGHTS
- who: Kentaro Tokumo and collaborators from the Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi, Minami-ku, Hiroshima, Japan have published the article: Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, in the Journal: (JOURNAL)
- what: The aim of this study was to investigate whether PAI-1 is involved in tolerance and whether it could be a therapeutic target for overcoming this tolerance. In this context, the authors focused on tolerant cells immediately after the start of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.